Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(12):1869–1876. doi: 10.1038/bjc.1996.647

Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

S Withoff 1, E G de Vries 1, W N Keith 1, E F Nienhuis 1, W T van der Graaf 1, D R Uges 1, N H Mulder 1
PMCID: PMC2074800  PMID: 8980384

Abstract

Sublines of the human small-cell lung carcinoma (SCLC) cell line GLC4 with acquired resistance to teniposide, amsacrine and mitoxantrone (GLC4/VM20x, GLC4/AM3x and GLC4/MIT60x, respectively) were derived to study the contribution of DNA topoisomerase II alpha and -beta (TopoII alpha and -beta) to resistance for TopoII-targeting drugs. The cell lines did not overexpress P-glycoprotein or the multidrug resistance-associated protein but were cross-resistant to other TopoII drugs. GLC4/VM20x showed a major decrease in TopoII alpha protein (54%; for all assays presented in this paper the GLC4 level was defined to be 100%) without reduction in TopoII beta protein; GLC4/AM3x showed only a major decrease in TopoII beta protein (to 18%) and not in TopoII alpha. In GLC4/MIT60x, the TopoII alpha and -beta protein levels were both decreased (TopoII alpha to 31%; TopoII beta protein was undetectable). The decrease in TopoII alpha protein in GLC4/VM20x and GLC4/MIT60x, was mediated by decreased TopoII alpha mRNA levels. Loss of TopoII alpha gene copies contributed to the mRNA decrease in these cell lines. Only in the GLC4/MIT60x cell line was an accumulation defect observed for the drug against which the cell line was made resistant. In conclusion, TopoII alpha and -beta levels were decreased differentially in the resistant cell lines, suggesting that resistance to these drugs may be mediated by a decrease in a specific isozyme.

Full text

PDF
1869

Images in this article

1872Figure 1
on p.1872
1874Figure 3
on p.1874

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin C. A., Sng J. H., Patel S., Fisher L. M. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283–291. doi: 10.1016/0167-4781(93)90215-y. [DOI] [PubMed] [Google Scholar]
  2. Beck J., Niethammer D., Gekeler V. High mdr1- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett. 1994 Oct 28;86(1):135–142. doi: 10.1016/0304-3835(94)90190-2. [DOI] [PubMed] [Google Scholar]
  3. Beck W. T., Danks M. K., Wolverton J. S., Chen M., Granzen B., Kim R., Suttle D. P. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol. 1994;29B:145–169. doi: 10.1016/s1054-3589(08)61136-9. [DOI] [PubMed] [Google Scholar]
  4. Boritzki T. J., Wolfard T. S., Besserer J. A., Jackson R. C., Fry D. W. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol. 1988 Nov 1;37(21):4063–4068. doi: 10.1016/0006-2952(88)90096-2. [DOI] [PubMed] [Google Scholar]
  5. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  6. Coutts J., Plumb J. A., Brown R., Keith W. N. Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer. 1993 Oct;68(4):793–800. doi: 10.1038/bjc.1993.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Covey J. M., Kohn K. W., Kerrigan D., Tilchen E. J., Pommier Y. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res. 1988 Feb 15;48(4):860–865. [PubMed] [Google Scholar]
  8. Danks M. K., Qiu J., Catapano C. V., Schmidt C. A., Beck W. T., Fernandes D. J. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol. 1994 Nov 1;48(9):1785–1795. doi: 10.1016/0006-2952(94)90465-0. [DOI] [PubMed] [Google Scholar]
  9. Dokter W. H., Esselink M. T., Halie M. R., Vellenga E. Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. Blood. 1993 Jan 15;81(2):337–343. [PubMed] [Google Scholar]
  10. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  11. Feldhoff P. W., Mirski S. E., Cole S. P., Sullivan D. M. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res. 1994 Feb 1;54(3):756–762. [PubMed] [Google Scholar]
  12. Flens M. J., Izquierdo M. A., Scheffer G. L., Fritz J. M., Meijer C. J., Scheper R. J., Zaman G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994 Sep 1;54(17):4557–4563. [PubMed] [Google Scholar]
  13. Fry A. M., Chresta C. M., Davies S. M., Walker M. C., Harris A. L., Hartley J. A., Masters J. R., Hickson I. D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 1991 Dec 15;51(24):6592–6595. [PubMed] [Google Scholar]
  14. Guchelaar H. J., Timmer-Bosscha H., Dam-Meiring A., Uges D. R., Oosterhuis J. W., de Vries E. G., Mulder N. H. Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer. 1993 Sep 30;55(3):442–447. doi: 10.1002/ijc.2910550320. [DOI] [PubMed] [Google Scholar]
  15. Harker W. G., Slade D. L., Parr R. L., Feldhoff P. W., Sullivan D. M., Holguin M. H. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr 15;55(8):1707–1716. [PubMed] [Google Scholar]
  16. Howard M. T., Neece S. H., Matson S. W., Kreuzer K. N. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12031–12035. doi: 10.1073/pnas.91.25.12031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kimura K., Saijo M., Ui M., Enomoto T. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem. 1994 Jan 14;269(2):1173–1176. [PubMed] [Google Scholar]
  19. Ling V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer. 1992 May 15;69(10):2603–2609. doi: 10.1002/1097-0142(19920515)69:10<2603::aid-cncr2820691034>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  20. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  21. Ma L., Krishnamachary N., Center M. S. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry. 1995 Mar 14;34(10):3338–3343. doi: 10.1021/bi00010a024. [DOI] [PubMed] [Google Scholar]
  22. Meijer C., Mulder N. H., Timmer-Bosscha H., Zijlstra J. G., de Vries E. G. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res. 1987 Sep 1;47(17):4613–4617. [PubMed] [Google Scholar]
  23. Murphy D. S., McHardy P., Coutts J., Mallon E. A., George W. D., Kaye S. B., Brown R., Keith W. N. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer. 1995 Feb 20;64(1):18–26. doi: 10.1002/ijc.2910640106. [DOI] [PubMed] [Google Scholar]
  24. Müller M., Meijer C., Zaman G. J., Borst P., Scheper R. J., Mulder N. H., de Vries E. G., Jansen P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13033–13037. doi: 10.1073/pnas.91.26.13033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nitiss J. L., Liu Y. X., Harbury P., Jannatipour M., Wasserman R., Wang J. C. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 1992 Aug 15;52(16):4467–4472. [PubMed] [Google Scholar]
  26. Pommier Y., Leteurtre F., Fesen M. R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12(5):530–542. doi: 10.3109/07357909409021413. [DOI] [PubMed] [Google Scholar]
  27. Tan K. B., Dorman T. E., Falls K. M., Chung T. D., Mirabelli C. K., Crooke S. T., Mao J. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 1992 Jan 1;52(1):231–234. [PubMed] [Google Scholar]
  28. Timmer-Bosscha H., Hospers G. A., Meijer C., Mulder N. H., Muskiet F. A., Martini I. A., Uges D. R., de Vries E. G. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst. 1989 Jul 19;81(14):1069–1075. doi: 10.1093/jnci/81.14.1069. [DOI] [PubMed] [Google Scholar]
  29. Versantvoort C. H., Withoff S., Broxterman H. J., Kuiper C. M., Scheper R. J., Mulder N. H., de Vries E. G. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer. 1995 May 4;61(3):375–380. doi: 10.1002/ijc.2910610317. [DOI] [PubMed] [Google Scholar]
  30. Withoff S., Keith W. N., Knol A. J., Coutts J. C., Hoare S. F., Mulder N. H., de Vries E. G. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer. 1996 Aug;74(4):502–507. doi: 10.1038/bjc.1996.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Withoff S., Smit E. F., Meersma G. J., van den Berg A., Timmer-Bosscha H., Kok K., Postmus P. E., Mulder N. H., de Vries E. G., Buys C. H. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest. 1994 Jul;71(1):61–66. [PubMed] [Google Scholar]
  32. Woessner R. D., Chung T. D., Hofmann G. A., Mattern M. R., Mirabelli C. K., Drake F. H., Johnson R. K. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res. 1990 May 15;50(10):2901–2908. [PubMed] [Google Scholar]
  33. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214. [PubMed] [Google Scholar]
  34. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zijlstra J. G., de Vries E. G., Mulder N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987 Apr 1;47(7):1780–1784. [PubMed] [Google Scholar]
  36. Zini N., Santi S., Ognibene A., Bavelloni A., Neri L. M., Valmori A., Mariani E., Negri C., Astaldi-Ricotti G. C., Maraldi N. M. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp Cell Res. 1994 Feb;210(2):336–348. doi: 10.1006/excr.1994.1046. [DOI] [PubMed] [Google Scholar]
  37. de Jong S., Kooistra A. J., de Vries E. G., Mulder N. H., Zijlstra J. G. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res. 1993 Mar 1;53(5):1064–1071. [PubMed] [Google Scholar]
  38. de Jong S., Zijlstra J. G., Mulder N. H., de Vries E. G. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol. 1991;28(6):461–464. doi: 10.1007/BF00685823. [DOI] [PubMed] [Google Scholar]
  39. de Jong S., Zijlstra J. G., de Vries E. G., Mulder N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990 Jan 15;50(2):304–309. [PubMed] [Google Scholar]
  40. van der Graaf W. T., de Vries E. G., Timmer-Bosscha H., Meersma G. J., Mesander G., Vellenga E., Mulder N. H. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res. 1994 Oct 15;54(20):5368–5373. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES